Recombinant BCG vaccine expressing multistage antigens of Mycobacterium tuberculosis provides long-term immunity against tuberculosis in BALB/c mice

References

• WHO. Global tuberculosis report 2022. World Health Organization; 2022. https://www.who.int/teams/global-tuberculosis-programme/tb-reports.
   Google Scholar
• Houben R, Dodd P, Metcalfe JZ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016;13(10):e1002152. doi:10.1371/journal.pmed.1002152.
   PubMed Web of Science ®Google Scholar
• Fine PE. Variation in protection by bcg: implications of and for heterologous immunity. Lancet (London, England). 1995 Nov;346(8986):1339–11. doi:10.1016/s0140-6736(95)92348-9.
   PubMed Web of Science ®Google Scholar
• Tait DR, Hatherill M, Van Der Meeren O, Ginsberg AM, Van Brakel E, Salaun B, Scriba TJ, Akite EJ, Ayles HM, Bollaerts A, et al. Final analysis of a trial of M72/AS01 E vaccine to prevent tuberculosis. N Engl J Med. 2019 Dec;381(25):2429–39. doi:10.1056/NEJMoa1909953.
   PubMed Web of Science ®Google Scholar
• Serbina NV, Lazarevic V, Flynn JL. CD4+ T cells are required for the development of cytotoxic CD8+ T cells during mycobacterium tuberculosis infection. J Immunol. 2001 Dec;167(12):6991–7000. doi:10.4049/jimmunol.167.12.6991.
   PubMed Web of Science ®Google Scholar
• Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med. 1999 Feb;340(5):367–373. doi:10.1056/nejm199902043400507.
   PubMed Web of Science ®Google Scholar
• Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, et al. Safety and efficacy of mva85a, a new tuberculosis vaccine, in infants previously vaccinated with bcg: a randomised, placebo-controlled phase 2b trial. Lancet. 2013 Mar;381(9871):1021–1028. doi:10.1016/s0140-6736(13)60177-4.
   PubMed Web of Science ®Google Scholar
• Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ, Schreiber R, Mak TW, Bloom BR. Tumor necrosis factor-α is required in the protective immune response against mycobacterium tuberculosis in mice. Immunity. 1995;2(6):561–72. doi:10.1016/1074-7613(95)90001-2.
   PubMed Web of Science ®Google Scholar
• Dooms H, Wolslegel K, Lin P, Abbas AK. Interleukin-2 enhances CD4+ T cell memory by promoting the generation of IL-7Rα–expressing cells. J Exp Med. 2007 Mar 19;204(3):547–57. doi:10.1084/jem.20062381.
   PubMed Web of Science ®Google Scholar
• Feng CG, Jankovic D, Kullberg M, Cheever A, Scanga CA, Hieny S, Caspar P, Yap GS, Sher A. Maintenance of pulmonary th1 effector function in chronic tuberculosis requires persistent il-12 production. J Immunol. 2005 Apr 1;174(7):4185–4192. doi:10.4049/jimmunol.174.7.4185.
   PubMed Web of Science ®Google Scholar
• Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, Cilley GE, Shen F, Eaton SM, Gaffen SL, Swain SL, et al. Il-23 and il-17 in the establishment of protective pulmonary cd4(+) t cell responses after vaccination and during mycobacterium tuberculosis challenge. Nat Immunol. 2007 Apr;8(4):369–77. doi:10.1038/ni1449.
   PubMed Web of Science ®Google Scholar
• Rothchild A, Jayaraman P, Nunes-Alves C, Behar S, Lewinsohn DM. Inkt cell production of gm-csf controls mycobacterium tuberculosis. PLoS Pathog. 2014;10(1):e1003805. doi:10.1371/journal.ppat.1003805.
   PubMed Web of Science ®Google Scholar
• Lu LL, Chung AW, Rosebrock TR, Ghebremichael M, Yu WH, Grace PS, Schoen MK, Tafesse F, Martin C, Leung V, et al. A functional role for antibodies in tuberculosis. Cell. 2016 Oct;167(2):433–43.e14. doi:10.1016/j.cell.2016.08.072.
   PubMed Web of Science ®Google Scholar
• Painter H, Prabowo SA, Cia F, Stockdale L, Tanner R, Willcocks S, Reljic R, Fletcher HA, Zelmer A. Adaption of the ex vivo mycobacterial growth inhibition assay for use with murine lung cells. Sci Rep. 2020 Feb; 10;10(1). doi:10.1038/s41598-020-60223-y.
   Web of Science ®Google Scholar
• Sterne JA, Rodrigues LC, Guedes IN. Does the efficacy of bcg decline with time since vaccination? Int J Tuberc Lung Dis. 1998 Mar;2(3):200–7.
   PubMed Web of Science ®Google Scholar
• Pym AS, Brodin P, Majlessi L, Brosch R, Demangel C, Williams A, Griffiths KE, Marchal G, Leclerc C, Cole ST. Recombinant bcg exporting esat-6 confers enhanced protection against tuberculosis. Nat Med. 2003 May;9(5):533–539. doi:10.1038/nm859.
   PubMed Web of Science ®Google Scholar
• Barber DL. The helper t cell’s dilemma in tuberculosis. Cell Host Microbe. 2017 Jun 14;21(6):655–656. doi:10.1016/j.chom.2017.06.004.
   PubMed Web of Science ®Google Scholar
• Aagaard C, Hoang T, Dietrich J, Cardona PJ, Izzo A, Dolganov G, Schoolnik GK, Cassidy JP, Billeskov R, Andersen P. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med. 2011 Feb;17(2):189–194. doi:10.1038/nm.2285.
   PubMed Web of Science ®Google Scholar
• Fay A, Glickman MS, Viollier PH. An essential nonredundant role for mycobacterial dnak in native protein folding. PLoS Genet. 2014 Jul; 10;10(7):e1004516. doi:10.1371/journal.pgen.1004516.
   PubMed Web of Science ®Google Scholar
• Trutneva KA, Shleeva MO, Demina GR, Vostroknutova GN, Kaprelyans AS. One-year old dormant, “non-culturable” mycobacterium tuberculosis preserves significantly diverse protein profile. Front Cell Infect Microbiol. 2020 Jan; 10;10. doi:10.3389/fcimb.2020.00026.
   PubMed Web of Science ®Google Scholar
• Fan X, Li X, Wan K, Zhao X, Deng Y, Chen Z, Luan X, Lu S, Liu H. Construction and immunogenicity of a t cell epitope-based subunit vaccine candidate against mycobacterium tuberculosis. Vaccine. 2021 Nov 16;39(47):6860–6865. doi:10.1016/j.vaccine.2021.10.034.
   PubMed Web of Science ®Google Scholar
• Ahn SK, Tran V, Leung A, Ng M, Li M, Liu J. Recombinant bcg overexpressing phop-phor confers enhanced protection against tuberculosis. Mol Ther. 2018 Dec:26(12):2863–2874. doi:10.1016/j.ymthe.2018.08.023.
   PubMed Web of Science ®Google Scholar
• Pooran A, Davids M, Nel A, Shoko A, Blackburn J, Dheda K. Il-4 subverts mycobacterial containment in mycobacterium tuberculosis-infected human macrophages. Eur Respir J. 2019 Aug; 54:54(2):1802242. doi:10.1183/13993003.02242-2018.
   PubMed Web of Science ®Google Scholar
• Reed SG, Coler RN, Dalemans W, Tan EV, Dela Cruz EC, Basaraba RJ, Orme IM, Skeiky YAW, Alderson MR, Cowgill KD, et al. Defined tuberculosis vaccine, mtb72f/as02a, evidence of protection in cynomolgus monkeys. Proc Natl Acad Sci USA. 2009 Feb;106(7):2301–2306. doi:10.1073/pnas.0712077106.
   PubMed Web of Science ®Google Scholar
• Hamza T, Barnett JB, Li BY. Interleukin 12 a key immunoregulatory cytokine in infection applications. Int J Mol Sci. 2010 Mar;11(3):789–806. doi:10.3390/ijms11030789.
   PubMed Web of Science ®Google Scholar
• O’Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MPR. The immune response in tuberculosis. Annu Rev Immunol. 2013;31(1):475–527. doi:10.1146/annurev-immunol-032712-095939.
   PubMedGoogle Scholar
• Lindenstrom T, Agger EM, Korsholm KS, Darrah PA, Aagaard C, Seder RA, Rosenkrands I, Andersen P. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional cd4 memory t cells. J Immunol. 2009 Jun;182(12):8047–8055. doi:10.4049/jimmunol.0801592.
   PubMed Web of Science ®Google Scholar
• Caccamo N, Guggino G, Joosten SA, Gelsomino G, Di Carlo P, Titone L, Galati D, Bocchino M, Matarese A, Salerno A, et al. Multifunctional CD4 + T cells correlate with active Mycobacterium tuberculosis infection. Eur J Immunol. 2010 Aug;40(8):2211–20. doi:10.1002/eji.201040455.
   PubMed Web of Science ®Google Scholar
• Day CL, Abrahams DA, Lerumo L, van Rensburg EJ, Stone L, O’Rie T, Pienaar B, de Kock M, Kaplan G, Mahomed H, et al. Functional capacity of mycobacterium tuberculosis-specific t cell responses in humans is associated with mycobacterial load. J Immunol. 2011 Sep;187(5):2222–2232. doi:10.4049/jimmunol.1101122.
   PubMed Web of Science ®Google Scholar
• Komine-Aizawa S, Mizuno S, Kawano A, Hayakawa S, Matsuo K, Honda M. The induction of antigen 85b-specific cd8+ t cells by recombinant bcg protects against mycobacterial infection in mice. Int J Mol Sci. 2023 Jan; 24;24(2):966. doi:10.3390/ijms24020966.
   PubMed Web of Science ®Google Scholar
• Soares AP, Scriba TJ, Joseph S, Harbacheuski R, Murray RA, Gelderbloem SJ, Hawkridge A, Hussey GD, Maecker H, Kaplair G, et al. Bacillus Calmette-Guérin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles. J Immunol. 2008 Mar;180(5):3569–77. doi:10.4049/jimmunol.180.5.3569.
   PubMed Web of Science ®Google Scholar
• Kaveh DA, Garcia-Pelayo MC, Hogarth PJ. Persistent bcg bacilli perpetuate cd4 t effector memory and optimal protection against tuberculosis. Vaccine. 2014 Dec 5;32(51):6911–6918. doi:10.1016/j.vaccine.2014.10.041.
   PubMed Web of Science ®Google Scholar
• Winchell CG, Nyquist SK, Chao MC, Maiello P, Myers AJ, Hopkins F, Chase M, Gideon HP, Patel KV, Bromley JD, et al. Cd8+ lymphocytes are critical for early control of tuberculosis in macaques. J Exp Med. 2023 Oct;220(12). doi:10.1084/jem.20230707.
   PubMed Web of Science ®Google Scholar
• Kudryavtsev I, Zinchenko Y, Serebriakova M, Akisheva T, Rubinstein A, Savchenko A, Borisov A, Belenjuk V, Malkova A, Yablonskiy P, et al. A key role of cd8+ t cells in controlling of tuberculosis infection. Diagnostics. 2023 Sep;13(18):2961. doi:10.3390/diagnostics13182961.
   Web of Science ®Google Scholar
• Li H, Wang XX, Wang B, Fu L, Liu G, Lu Y, Cao M, HR H, Javid B. Latently and uninfected healthcare workers exposed to tb make protective antibodies against mycobacterium tuberculosis. Proc Natl Acad Sci USA. 2017 May;114(19):5023–8. doi:10.1073/pnas.1611776114.
   PubMed Web of Science ®Google Scholar
• Li H, Javid B. Antibodies and tuberculosis: finally coming of age? Nat Rev Immunol. 2018 Sep;18(9):591–596. doi:10.1038/s41577-018-0028-0.
   PubMed Web of Science ®Google Scholar
• Zelmer A, Tanner R, Stylianou E, Damelang T, Morris S, Izzo A, Williams A, Sharpe S, Pepponi I, Walker B, et al. A new tool for tuberculosis vaccine screening: ex vivo mycobacterial growth inhibition assay indicates bcg-mediated protection in a murine model of tuberculosis. BMC Infect Dis. 2016 Aug 16;16 (1).doi:10.1186/s12879-016-1751-4.
   PubMedGoogle Scholar
• Tanner R, Hoogkamer E, Bitencourt J, White A, Boot C, Sombroek CC, Harris SA, O’Shea MK, Wright D, Wittenberg R, et al. The in vitro direct mycobacterial growth inhibition assay (mgia) for the early evaluation of tb vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells. F1000Res. 2021;10:257. doi:10.12688/f1000research.51640.1.
   PubMedGoogle Scholar
• Wang RH, Fan XT, Jiang Y, Li GL, Li MC, Zhao XQ, Luan XL, Deng YL, Chen ZX, Liu HC, et al. Immunogenicity and efficacy analyses of epc002, eca006, and epcp009 protein subunit combinations as tuberculosis vaccine candidates. Vaccine. 2023 Jun;41(26):3836–3846. doi:10.1016/j.vaccine.2023.04.003.
   PubMed Web of Science ®Google Scholar
• Yu JJ, Fan XT, Luan XL, Wang RH, Cao B, Qian CY, Li GL, Li MC, Zhao XQ, Liu HC, et al. A novel multi-component protein vaccine ecp001 containing a protein polypeptide antigen npsts1 riching in t-cell epitopes showed good immunogenicity and protection in mice. Front Immunol. 2023 Apr; 14; 14. doi:10.3389/fimmu.2023.1138818.
   Web of Science ®Google Scholar
• Shoulah SA, Gaballa MM, Elshafae SM, Moussa MA, Selim A, Wakid MH. Evaluation of the immunopathological response to bcg vaccine in a xenogeneic immunocompetent animal. Kafkas Universitesi Veteriner Fakultesi Dergisi. 2023 May-Jun;29:281–8. doi:10.9775/kvfd.2023.29187.
   Web of Science ®Google Scholar